CEL-SCI Corp (CVM) – Hot FDA News
-
CEL-SCI Corp (CVM) Multikine Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
-
CEL-SCI Corp (CVM) Announces Early Results with COVID 19 LEAPS Vaccine/Treatment
-
-
-
Back to CVM Stock Lookup